Live from the NIH registry
Studies recruiting near Eugene right now
Top 25 of 148 recruiting studies, sorted by proximity — each links to its official registry page
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Limited Stage Small Cell Lung Cancer
Phase 2
Interventional 250 participants sought
Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center) — Eugene, Oregon (1.6 mi)
· Sponsor: SCRI Development Innovations, LLC
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Ovarian Cancer, Fallopian Tube Cancer
Phase 2
Interventional 270 participants sought
517 — Eugene, Oregon (1.6 mi)
· Sponsor: Corcept Therapeutics
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
Phase 3
Interventional 570 participants sought
Willamette Valley Cancer Institute — Eugene, Oregon (1.6 mi)
· Sponsor: Immuneering Corporation
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
Benign Prostatic Hyperplasia
N/A
Interventional 92 participants sought
Oregon Urology Institute — Springfield, Oregon (4.8 mi)
· Sponsor: Urotronic Inc.
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast Neoplasms, Neoplasm Metastasis
Phase 3
Interventional 800 participants sought
Oncology Associates of Oregon — Eugene, Oregon (1.6 mi)
· Sponsor: Eli Lilly and Company
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2
Interventional 310 participants sought
Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon — Eugene, Oregon (1.6 mi)
· Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple Negative Breast Cancer
Phase 3
Interventional 1,514 participants sought
Willamette Valley Cancer Institute and Research Center — Eugene, Oregon (1.6 mi)
· Sponsor: Gilead Sciences
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Phase 2
Interventional 130 participants sought
Oncology Associates of Oregon, P.C — Eugene, Oregon (1.6 mi)
· Sponsor: Hoffmann-La Roche
A Study of Dual-task Exercise Training to Prevent Falls Among Older Adults With Mild Cognitive Impairment
Mild Cognitive Impairment, Accidental Falls
N/A
Interventional 336 participants sought
Oregon Research Institute — Springfield, Oregon (4.8 mi)
· Sponsor: Oregon Research Institute
A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
Myeloproliferative Neoplasms (MPNs)
Phase 1
Interventional 250 participants sought
Site US20 — Eugene, Oregon (1.6 mi)
· Sponsor: Damora Therapeutics
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking
Keratoconus, Unstable, Bacterial Keratitis
Phase 1
Interventional 300 participants sought
Pacific Clear Vision Institute — Eugene, Oregon (1.6 mi)
· Sponsor: Pacific Clear Vision Institute
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Phase 3
Interventional 170 participants sought
Willamette Valley Cancer Institute and Research Center /ID# 266326 — Eugene, Oregon (1.6 mi)
· Sponsor: AbbVie
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Phase 2, Phase 3
Interventional 690 participants sought
Oncology Associates Of Oregon, Pc — Eugene, Oregon (1.6 mi)
· Sponsor: Bristol-Myers Squibb
Testing Just-in-Time Adaptive Interventions (JITAIs) to Prevent Goal Disengagement in Response to Weight Regain
Overweight or Obesity
N/A
Interventional 120 participants sought
Oregon Research Institute Community and Evaluation Services — Springfield, Oregon (4.8 mi)
· Sponsor: ORI Community and Evaluation Services
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase
Phase 1, Phase 2
Interventional 330 participants sought
Willamette Valley Cancer Institute and Research Center — Eugene, Oregon (1.6 mi)
· Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
Chronic Low-back Pain, Vertebrogenic Pain Syndrome
N/A
Observational 1,500 participants sought
Pacific Sports and Spine — Eugene, Oregon (1.6 mi)
· Sponsor: Boston Scientific Corporation
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic
Phase 3
Interventional 680 participants sought
Oncology Associates of Oregon, P.C. — Eugene, Oregon (1.6 mi)
· Sponsor: Pfizer
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic Atrophy, Macular Degeneration
N/A
Observational 500 participants sought
Verum Research, LLC — Eugene, Oregon (1.6 mi)
· Sponsor: Astellas Pharma Global Development, Inc.
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Phase 3
Interventional 231 participants sought
Site Number - 1031 — Eugene, Oregon (1.6 mi)
· Sponsor: Immunovant Sciences GmbH
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Phase 3
Interventional 500 participants sought
Oncology Associates of Oregon Willamette Valley Cancer Center — Eugene, Oregon (1.6 mi)
· Sponsor: BeOne Medicines
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Phase 3
Interventional 850 participants sought
Oncology Associates Of Oregon, Pc — Eugene, Oregon (1.6 mi)
· Sponsor: Bristol-Myers Squibb
Garden-fresh Foods and Gut Microbiomes
Gut Microbiome
N/A
Interventional 20 participants sought
Institute for Health in the Built Environment, University of Oregon — Eugene, Oregon (1.6 mi)
· Sponsor: University of Oregon
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
Substance Abuse, Decision Making, Shared
N/A
Interventional 341 participants sought
Chestnut Health Systems — Eugene, Oregon (1.6 mi)
· Sponsor: Chestnut Health Systems
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 2
Interventional 140 participants sought
Oncology Associates of Oregon, P.C. /ID# 275006 — Eugene, Oregon (1.6 mi)
· Sponsor: AbbVie
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Colon Cancer, Rectal Cancer
Phase 2
Interventional 60 participants sought
Oncology Associates of Oregon - Primary — Eugene, Oregon (1.6 mi)
· Sponsor: SCRI Development Innovations, LLC